Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca displays results of key phase II trial for Zactama

AstraZeneca displays results of key phase II trial for Zactama

6th June 2006

The UK’s second largest pharmaceutical company has revealed the latest phase II trial results for Zactama, a new treatment for advanced non-small cell lung cancer (NSCLC).

Zactama, also known as ZD6474, is designed to target multiple signalling pathways that are responsible for tumour growth, unlike several existing anti-cancer drugs, which are designed to target one particular signalling pathway. The notion behind the new drug design is that the more tumour cell signalling pathways that can be disabled or limited, the better the chance that progression free survival (PFS) can be maximised.

Zactama inhibits both the development of blood supply to tumours and the growth of the tumour itself.

In one of the studies, patients who had the option to choose between taking Zactama and Iressa found that their disease was controlled for more than eight weeks 43 per cent of the time with Zactama, in comparison to 24 per cent of the time with Iressa, a relatively new AstraZeneca drug also used for the treatment of NSCLC.

John Heymach MD, of the University of Texas’ Anderson Cancer Centre, remarked: “ZD6474 is the first multi-targeted agent to show anti-tumour activity both when used in combination with standard chemotherapy and as a single agent.”

“Given the poor prognosis in lung cancer, an increase in PFS is meaningful for patients. These promising data have led to the initiation of phase III evaluation of ZD6474,” he added.

AstraZeneca hopes to begin enrolment for study 32, the first phase III evaluation of the drug, involving 1,200 worldwide.

The results were presented at the American Society of Clinical Oncology’s annual meeting. AstraZeneca will also present further results for Zactama for use in patients with hereditary medullary thyroid cancer.

Hereditary medullary thyroid cancer often has a poorer prognosis than other types of thyroid cancer.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.